Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
Hi crumbs
We can now see that Moditope does not obliterate cancer tumours that are at such a mature stage. Patients that have undergone Chemo and their tumour has not been vanquished probably end up with a very hard to treat biome. Moditope in this setting does not have the range or scope to eradicate a person's individual tumour.
As this trial progresses Scancell will discover where it is most effective.
My take is that we had to engage at the most difficult end of the spectrum to be able to find enough patients willing to take part in our trial. There are some very important lessons being learnt and I back Lindy and her team to navigate their way towards the correct position for Modi1. It may end up being in earlier stages or in combination with CPI's.
It may even be in combo with Modi2. You never know.
Chester.
Thank you both for your responses.
I realise these mammoth acquisitions do take time to come together. It would seem from you have said the vote will be within the next four to six weeks.
All the best
Chester.
I've not posted here for quite some time. Still hold a few 100k's of shares
Please excuse my ignorance but when will Newcrest shareholders actually get he chance to vote on the proposed Newmont Takeover.
I'm aware it's in September but is there a specific date ?
Chester.
When the Macmillan story broke in Feb 2023 the SP rose on all the positive hype and then declined over time. This is now an opportunity for some negative hype.
We are two weeks out from CICON Milan and we have been told info about SCIB1 and Modi1 will be shared by Scancell.
This reaction to the Macmillan website post is understandable but this knee jerk response is as if Scancell don't know and we've found out before the company.
I hope for all those that have sold out that positive news doesn't drop on GenMab, or AvidiMab or GlyMab or BionTech and leave them scrambling back in.
Can we all please remember that Moditope cleared early, single biome tumours in mouse models. Our current patients have mature and very complex tumours and yet Moditope still is having an effect.
ModiFY is a work in progress and only Scancell know the scientific truth of its progress.
Chester
Hi C11
You are correct but my comment about October being the time for the SCIB1 read out is also correct. That Business Update RNS in July says 'SCOPE Trial to have Top Line Read Out Q4 2023'.
Q4 is Oct, Nov and Dec. Some interesting data will be announced at the Milan Conference but according to that RNS it won't be a full TopLine Data reveal.
We will know what was actually meant in just a few weeks time.
All the best
Chester.
September will see the arrival of our new Business Development Manager. Scancell have shown patience in getting their preferred choice for that role.
CICON Conference in Milan 20th to 22nd Sept.
October :
World Vaccine Conference 16th to 19th October. This is around the time we will start to hear how SCIB1- SCOPE Trial has progressed. Maybe some indication of when iSCIB1+ will be approved.
The Annual Results for year ending 30th April 2023 should be RNS'ed by the end of October with the date of the 2023 AGM confirmed.
Between the World Vaccine Conference and the year end accounts we should also have some details on the ModiFY trial progress.
Prior to the AGM ( late Nov ) we need to also hear what has happened to Modi2 and our potential TCB Antibdy. At the AGM if we have not heard beforehand we need full updates on, GenMab progress and potential of that deal moving to the next Milestone, BionTech and the ModiFY Activated 'T' Cells they wanted and have probably been supplied with already, what levels of intest have seen in our other Platforms, namely AvidiMab and GlyMabs.
Next 2 / 3 months are going to be very revealing and should be very positive for the SP, in my humble opinion.
Chester.
I would imagine that Sath met all our required criteria. He has gain plenty of experience in his career so far.
Most importantly he will have enough experience to suit Scancell and his wage will be in line with what we can currently afford.
Chester.
Hi Burble
Following that train of thought I would suggest that Scib1 is working well in the the patients that currently fit the correct profile. As we know this is a sub-set of melanoma patients.
The move to iSCIB+ triples the number of potential patients which means with the right data results it will be commercially extremely valuable.
The 'would' in that RNS says that a suitor has very possibly laid their cards in the table given iSCIB+ brings in the right level of positive data.
The sooner we are informed that we have approval to move the SCOPE trial to the newer version the better.
Chester.
Hi LochinvarLass
All we can go on is that for the last three years the AGM has been around the 3rd week of November.
We won't know for sure until its announced but Monday 20th November is my guess.
Hope you are keeping well.
Chester.
Hi Rookie1
Scib1 trial which is called 'SCOPE' has been progressing quietly in the background while all attention has been on Modi1, 'ModiFY Trial'.
If you have not closely followed the journey there are three things to note about SCIB1:
A) It is now a needle free injection using PharmaJet technology.
B ) We have been told there will be a full Data Readout by the end of the year, probably before the AGM in late November.
C ) SCIB1 is to be enhanced very soon with additional episodes and Scancell 'AvidiMab' platform that increases the potential binding of the drug to the target. It will become iSCIB+.
The SCOPE trial has been moving forward and is very close to enrolling the target number of trial patients. Another positive is the increase overtime of the number of clinical sites that have signed up to be part of the trial.
Our CEO said if you like SCIB1 you will love iSCIB+.
Hope that is a helpful starter for you.
Chester.
Thank you TF
August is holiday season so it can be very slow news wise. It would be excellent to have something to happen prior to the 19th of September but Scancell may have good reasons to delay any news until they are at those conferences.
I'm staying very positive and hoping that GenMab are progressing towards a phase one trial with our Glymab target π€π€
Thank you TF
August is holiday season so it can be very slow news wise. It would be excellent to have something to happen prior to the 19th of September but Scancell may have good reasons to delay any news until they are at those conferences.
I'm staying very positive and hoping that GenMab are progressing towards a phase one trial with our Glymab target π€π€
I've just listened to that Pod Cast. It just shows how difficult it is to convince Large Pharma and Clinicians to move from the tried and tested 'known' to the new 'unknown', without solid data.
Mid 1990's presenting a Checkpoint Inhibitor to 30 or so at a conference and being told that changing the tumour micro enviroment was bunkum and what was needed were better drugs.
Now 25 years later Immuno-Oncology the biggest rooms at conferences with 3,000 to 4,000 in attendance.
Our ModiFY Trial has had to begin by seeing if we can make a difference to the most poorly of cancer patients. The reason is partly due to the successful adoption of Checkpoint Inhibitors in earlier patients.
Both of Scancells Trials are progressing positively and its only a matter of time before we get those fuller trial readouts.
ModiFY could have a 6 month update later this month π€and the Scope Trial update is promised by the end off this year.
Nobody enjoys newsless periods of time but the September Conferences will be here really soon.
Chester.
SCIB1 Scope Trial :
Progressing well, soon to transit to iSCIB+.
Promise of Full Update on Scope Trial by December.
iSCIB1+, first data mid to late 2024.
GlyMabs / GenMab deal, we are already Β£5m up and we have a very good chance of the next Milestone payment. The deal is 10 months old in August plus we are told, more deals are being discussed.
Finances are solid until next May / June, plenty of time to get a few deals over the line. We can concern ourselves with that next March / April, if nothing has generated some spending money.
Modi1 'mono' : (Safe and No major Toxicity issues)
Head & Neck ( regression seen in at least 1 patient )π
Ovarian ( 44% of patients treated having stable disease ) π
Renal π
TNBC ( late stage ) needs help of CPI plus at earlier stage intervention we may see a more significant result.
Modi1 + CPI :
Head & Neck ( regression seen in first patient ) π
Renal ( TBA ) but moving forward π
Ovarian and TNBC both need a Pharma Partner to promote a Modi1 + CPI Trial.
As trials go there are a lot of positive results across Scope and ModiFY.
Chester.
Hi krafty1305
Excellent news today and as you say putting Modi1 aside, I feel the next big Scancell news will be about the GenMab deal.
GenMab signed that deal just over 9 months ago ( 25th October 2022 ). LD said in the, Proactive Investors in person interview, that GenMab were reported to be very happy with our Antibody Target and Scancell were excited about the prospects of that deal proceeding towards the next milestone ( or words to that effect ).
I am still hoping that we will also receive a more comprehensive Modi1 progress report during August with numbers of patients dosed, a table of results from scans, how many patients have completed 1st stage treatment ( 5 doses ) and the outcomes seen at 24 weeks Scans. Similar to the RNS on Feb 21st at 8 weeks Scans.
Chester.
Hi C11
I realise you can read my post as overly negative on the chances of our success, but I was putting forward my frustration about the timing and the random coverage of that July 10th RNS.
We were all waiting for the next significant data read out from ModiFy. I don't think anyone would have been surprised if there was no mention of the SCOPE trial because it had become just a background story, for now.
The information contained in the RNS was luke warm on ModiTope, big on Scib1 plus CPI, but that was going to be delayed so we can ( very rightly ) upgrade to iSCIB+.
The 6 month evaluation of our GlyMab products is great news but 6 months away and only a maybe.
In the current financial battle with inflation and interest rates we definitely did not need to present our cash flow as anything other than, we have cash for over a year and are in talks with several companies to do deals.
Many of us that have been around a while have supported the company in their past fund raisings. We are not Redmile who are collecting interest payments every month on their CLN's.
The big investor that is feeling our pain is Vulpes who invested Β£m's before Redmile arrived and they will be reeling at the current sub 10p shareprice.
Just my opinion as explained to Dracula1 why I am frustrated with the lack of shareholder consideration in the pitch and tone of that RNS.
I do think that we are now back to Radio Silence until September, I do hope I am wrong though.
We will have to wait and see.
Chester.